Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Genitourinary 2Other solid neoplasm 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 57pembrolizumab 54Cetuximab 43Radiotherapy 35Docetaxel 21Radiotherapy, Intensity-Modulated 20Paclitaxel 19Nivolumab 18Fluorouracil 18Carboplatin 17Radiation 14Radiosurgery 9Magnetic Resonance Spectroscopy 8Gemcitabine 8Everolimus 8Biopsy 8Surgical Procedures, Operative 7Oxaliplatin 7Cyclophosphamide 7durvalumab 6avelumab 6Erlotinib Hydrochloride 6Capecitabine 6spartalizumab 5epacadostat 5Surveys and Questionnaires 5Platinum 5Immunoglobulin G 5Gefitinib 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Radiation Dose Hypofractionation × Head & Neck × Clear all
NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
14 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02201355 2021-02-02

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

University of Texas Southwestern Medical Center

Phase 1 Terminated
8 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡